Natera’s lung transplant biomarker study validates noninvasive dd-cfDNA surveillance model
Can a blood test replace lung biopsies? Natera’s Prospera test may reshape transplant care. Learn what the latest study means for diagnostics in organ health.
Genethon advances Duchenne gene therapy trial while licensing Pompe tech to Bayer’s AskBio
Genethon advances gene therapies for Duchenne and Pompe disease. Find out what its nonprofit model and AskBio licensing deal mean for rare disease care.
Eisai and Biogen advance injectable Alzheimer’s therapy with FDA fast-track decision
FDA fast-tracks Eisai’s LEQEMBI IQLIK for at-home Alzheimer’s care. Find out what this means for patients, payers, and delivery models today.
Landmark FDA nod gives MSC developers long-awaited quality benchmark for clinical use
The FDA has recognized Tasly’s 3P assay as the first quality control standard for MSCs. Find out what this changes for developers and regulators.
Argo Biopharma’s RNAi therapy targets Lp(a): What Phase 2b with Novartis could prove
Novartis advances Argo Biopharma’s BW-20829 into Phase 2b to target lipoprotein(a). Explore what this means for RNAi adoption in cardiovascular therapeutics.
Is oral GLP-1 finally viable? Inside Ascletis Pharma’s U.S. trial for ASC30
Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.
FDA priority review for Leqembi Iqlik could transform Alzheimer’s drug initiation at home
Leqembi Iqlik gets FDA Priority Review for at-home Alzheimer’s treatment initiation. Find out what this could mean for patients, payers, and the care model.
Can edge AI help redefine acute care? What GE HealthCare and NXP’s anesthesia and NICU concepts reveal
When GE HealthCare and NXP Semiconductors N.V. took the stage at CES 2026 to showcase their collaboration, it marked more than a moment of tech theater. The partnership unveiled two forward-looking concept technologies that aim to apply edge artificial intelligence to some of the most demanding environments in medicine: the operating room and the neonatal […]
Syracuse Orthopedic Specialists and three affiliates join Evolve Orthopedic Partners platform
Evolve Orthopedic Partners expands its musculoskeletal platform with four-practice deal in New York. Find out how this model could redefine MSO growth.
Can targeting neuropathy reverse tissue death? What the Rapid Nexus study means for chronic wound care
New study shows neuropathy reversal can restore healing in tissue facing amputation. Find out how Rapid Nexus could reshape wound care.